The pharmaceutical industry spent years fighting to overturn a 2022 law forcing drugmakers to negotiate Medicare drug prices with the federal government. Industry lawyers battled all the way to the Supreme Court and, fortunately for consumers, lost when the court declined to hear the case. AARP described the outcome as a “victory for older Americans and their budgets.” “AARP fought hard for this new law giving Medicare the power to negotiate low…
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.